Drug Treatments for Mastalgia: 17 Years Experience in the Cardiff Mastalgia Clinic

C. Gateley, Margaret Miers, R E Mansel, L E Hughes
In: Journal of the Royal Society of Medicine · 1992 · vol. 85(1) , pp. 12–15 · doi:10.1177/014107689208500105 · PMID:1548647 · W1868014125
article OA: bronze CC0 ⤵ 8 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This 17-year experience at the Cardiff Mastalgia Clinic found danazol most effective for mastalgia, with bromocriptine and evening primrose oil showing equivalent efficacy but fewer adverse events for the latter.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Mastalgia commonly presents to medical practitioners. The majority of patients can be managed by exclusion of cancer and reassurance. In some the severity of pain affects the quality of life and drug treatment should be considered. Since its inception 324 patients with cyclical mastalgia and 90 with non-cyclical mastalgia have received a therapeutic trial of drug treatment in the Cardiff Mastalgia Clinic. Overall 92% of those with cyclical mastalgia and 64% with non-cyclical mastalgia obtained a clinically useful response to therapy. Danazol was the most effective drug, with bromocriptine and evening primrose oil having equivalent efficacy. Many fewer adverse events were complained of by patients treated with evening primrose oil than danazol or bromocriptine.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (9)

Cited by (5)

Source provenance

openalex
last seen: 2026-05-10T10:24:21.966905+00:00
License: CC0 · commercial use OK